Fiche publication
Date publication
décembre 2024
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Mme TRUNTZER Caroline
,
Dr VINCENT Julie
,
Dr BENGRINE-LEFEVRE Leila
,
Dr ORRY David
,
Dr DERANGERE Valentin
,
Dr HENNEQUIN Audrey
Tous les auteurs :
Fourrier T, Truntzer C, Peroz M, Derangère V, Vincent J, Bengrine-Lefèvre L, Hennequin A, Palmier R, Orry D, Rabel T, Ghiringhelli F
Lien Pubmed
Résumé
Metastatic colorectal cancer (mCRC) is mainly treated with 5-Fluoro-Uracil (5-FU), Oxaliplatin and Irinotecan chemotherapies and anti-Epidermal Growth Factor Receptor (EGFR) or anti-Vascular Endothelial Growth Factor (VEGF) targeted therapies. Due to chemotherapy-related toxicity, patients receive induction treatment to achieve tumour response followed by maintenance therapy with less cytotoxic molecules or a chemotherapy-free interval to reduce chemotherapy-related toxicity. In this study, the aim was to determine the patient, cancer and treatment factors that influence the duration of maintenance therapy (DMT).
Mots clés
chemotherapy, induction treatment, maintenance treatment, metastatic colorectal cancer, targeted therapies
Référence
Cancers (Basel). 2024 12 30;17(1):
